Lactobacillus Restructures the Micro/Mycobiome to Combat Inflammation-Mediated Right Ventricular Dysfunction in Pulmonary Arterial Hypertension
- 1 July 2025
- journal article
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 18 (7) , e012524
Abstract
BACKGROUND: Inflammation suppresses right ventricular (RV) function in pulmonary arterial hypertension (PAH). In particular, we showed GP130 (glycoprotein-130) signaling promotes pathological microtubule remodeling and RV dysfunction in rodent PAH. Emerging data demonstrate the intestinal microbiome regulates systemic inflammation, but the impact of modulating the gut microbiome on the GP130-microtubule axis in RV failure is unknown. METHODS: Two weeks following monocrotaline injection, rats were administered daily Lactobacillus rhamnosus (4×10 7 colony-forming units) via oral gavage for 10 days. Next-generation metagenomics and internal transcribed spacer 2 sequencing delineated fecal bacterial and fungal compositions. SomaScan proteomics measured levels of 7596 serum proteins. RV immunoblots quantified protein abundances. Light or super resolution confocal microscopy assessed RV, lung, and jejunal morphology. Echocardiography and invasive closed-chest pressure-volume loops evaluated PAH severity and RV function. The relationship between Lactobacillus abundance and RV function was assessed in 65 patients with PAH. RESULTS: Lactobacillus administration restructured both the intestinal micro- and mycobiome. The alteration in the gut ecosystem improved intestinal health as demonstrated by increased jejunal villus length and glycocalyx thickness and diminished intestinal permeability biomarkers. Serum proteomics revealed Lactobacillus modulated systemic inflammation and decreased circulating GP130 ligands. Lactobacillus -mediated suppression of GP130 signaling blunted pathological microtubule remodeling in RV cardiomyocytes. Microtubule-associated phenotypes, including RV cardiomyocyte and nuclear hypertrophy, transverse tubule integrity, and connexin-43 localization, were all corrected with Lactobacillus . These cellular changes manifested as improved RV function despite no significant alteration in PAH severity. Finally, patients with PAH and detectable fecal Lactobacillus had superior RV function despite similar mean pulmonary arterial pressure and pulmonary vascular resistance as compared with those without detectable Lactobacillus . CONCLUSIONS: Lactobacillus supplementation restructures the gut micro/mycobiome, restores intestinal health, dampens systemic inflammation, and reduces GP130 ligands and associated RV cardiomyocyte microtubule remodeling. These data identify a novel microbiome-inflammation-microtubule axis that has therapeutic relevance for RV dysfunction.Keywords
This publication has 65 references indexed in Scilit:
- Causal effects between gut microbiota and pulmonary arterial hypertension: A bidirectional Mendelian randomization studyHeart & Lung, 2024
- A unique gut microbiota signature in pulmonary arterial hypertension: A pilot studyPulmonary Circulation, 2022
- With No Lysine Kinase 1 Promotes Metabolic Derangements and RV Dysfunction in Pulmonary Arterial HypertensionJACC: Basic To Translational Science, 2021
- Treatment Targets for Right Ventricular Dysfunction in Pulmonary Arterial HypertensionJACC: Basic To Translational Science, 2020
- Lactobacillus rhamnosus GG and HbA1c in middle age and older adults without type 2 diabetes mellitus: A preliminary randomized studyDiabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020
- Anatomy and Physiology of the Small BowelGastrointestinal Endoscopy Clinics of North America, 2017
- Microtubule-Mediated Misregulation of Junctophilin-2 Underlies T-Tubule Disruptions and Calcium Mishandling in mdx MiceJACC: Basic To Translational Science, 2016
- Rodent Models of Group 1 Pulmonary Hypertension2013
- Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: A pilot studyPediatric Pulmonology, 2010
- Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: A pilot studyClinical Nutrition, 2007